Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


INTERVIEW: Goldman's dreams of competitive collaboration as IMI 2 considered

This article was originally published in Scrip

Executive Summary

With around €1.2 billion of the Innovative Medicines Initiative's €2 billion budget already spent financing around 40 projects, executive director Michel Goldman's thoughts are turning to the possibility of an IMI 2. He told Scrip in an exclusive interview that he believes the IMI's successes to date are enough to weigh in favor of another IMI scheme, and set out the case for more clinically-oriented elements for the next phase of IMI.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts